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Excitotoxicity is thought to play key roles in brain neurodegeneration and stroke. Here we show that neuroprotection against exci-
totoxicity by trophic factors EFNB1 and brain-derived neurotrophic factor (called here factors) requires de novo formation of ‘sur-
vival complexes’ which are factor-stimulated complexes of N-methyl-D-aspartate receptor with factor receptor and presenilin 1.
Absence of presenilin 1 reduces the formation of survival complexes and abolishes neuroprotection. EPH receptor B2- and N-me-
thyl-D-aspartate receptor-derived peptides designed to disrupt formation of survival complexes also decrease the factor-stimulated
neuroprotection. Strikingly, factor-dependent neuroprotection and levels of the de novo factor-stimulated survival complexes de-
crease dramatically in neurons expressing presenilin 1 familial Alzheimer disease mutants. Mouse neurons and brains expressing
presenilin 1 familial Alzheimer disease mutants contain increased amounts of constitutive presenilin 1–N-methyl-D-aspartate recep-
tor complexes unresponsive to factors. Interestingly, the stability of the familial Alzheimer disease presenilin 1–N-methyl-D-aspar-
tate receptor complexes differs from that of wild type complexes and neurons of mutant-expressing brains are more vulnerable to
cerebral ischaemia than neurons of wild type brains. Furthermore, N-methyl-D-aspartate receptor-mediated excitatory post-synaptic
currents at CA1 synapses are altered by presenilin 1 familial Alzheimer disease mutants. Importantly, high levels of presenilin 1–N-
methyl-D-aspartate receptor complexes are also found in post-mortem brains of Alzheimer disease patients expressing presenilin 1
familial Alzheimer disease mutants. Together, our data identify a novel presenilin 1-dependent neuroprotective mechanism against
excitotoxicity and indicate a pathway by which presenilin 1 familial Alzheimer disease mutants decrease factor-depended neuropro-
tection against excitotoxicity and ischaemia in the absence of Alzheimer disease neuropathological hallmarks which may form
downstream of neuronal damage. These findings have implications for the pathogenic effects of familial Alzheimer disease mutants
and therapeutic strategies.
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Introduction
Neurodegenerative disorders, including Alzheimer disease,
are characterized by progressive loss of specific neuronal
populations (Price et al., 2001), but the mechanisms
underlying this selective vulnerability are not fully under-
stood. Neuronal exposure to toxic insults, including glu-
tamate excitotoxicity, oxidative stress and ischaemia,
however, is believed to play crucial roles in chronic neu-
rodegenerative disorders such as Alzheimer disease and
Huntington diseases (Choi, 1988, 1995; Mattson, 2003;
Lipton, 2006). N-methyl-d-aspartate receptors
(NMDARs) play central roles in synaptic transmission,
plasticity, learning and memory but paradoxically,
NMDAR-associated excitotoxicity is also believed to play
central roles in neuronal death associated with
neurodegenerative diseases, stroke, ischaemia and trau-
matic brain injury (Arundine and Tymianski, 2003,
Hardingham, 2009, Parsons and Raymond, 2014). Thus,
it is generally accepted that proper activation of
NMDARs promotes neuronal survival while impaired or
excessive NMDAR activation leads to excitotoxicity,
pathological outcomes and neurodegeneration (Paoletti
et al., 2013; Parsons and Raymond, 2014). To counter
toxic insults, the brain develops neuroprotective mecha-
nisms some regulated by neuroprotective factors such as
brain-derived neurotrophic factor (BDNF) and EFNs
(ephrins) (Calo et al., 2006; Nagahara and Tuszynski,
2011; Barthet et al., 2013; Theus et al., 2014).
Mutations of the gene encoding the transmembrane
protein presenilin 1 (PS1) are responsible for most cases
of early onset autosomal dominant familial Alzheimer
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disease (FAD). Although the autosomal dominant pattern
of FAD transmission suggests these mutants may cause
gain of neurotoxic functions or dominant loss of essential
functions (Shen and Kelleher, 2007; Wolfe, 2007), the
mechanisms by which PS1 FAD mutants cause dominant
neurodegeneration remain poorly understood. PS1 has
been shown to have diverse functions including a crucial
role in the c-secretase complex that processes transmem-
brane proteins and mediates production of the Ab pepti-
des (Barthet et al., 2012; Haapasalo and Kovacs, 2011),
and in c-secretase-independent functions such as autoph-
agy (Lee et al., 2010), calcium homeostasis (Tu et al.,
2006), neurotransmitter release (Zhang et al., 2009) and
neuroprotection (Barthet et al., 2013). Of particular sig-
nificance to neuronal survival is the role of PS1 in media-
ting the neuroprotective functions of EFNB1 and BDNF
against excitotoxicity (Barthet et al., 2013). It is known
that BDNF and EFNs function in axon guidance, neuron-
al survival and synaptic activity and that they initiate cel-
lular signalling cascades by stimulating formation of
dynamic complexes of their cognate receptors with mul-
tiple proteins including the subunits of the NMDAR
(Suen et al., 1997; Dalva et al., 2000; Husi et al., 2000;
Henderson et al., 2001; Takasu et al., 2002; Wang et al.,
2011). Furthermore, literature reports in the last two dec-
ades show that BDNF- and EFNB-induced interactions of
their cognate receptors with the NMDAR regulate its
functions in long-term potentiation, cognition and disease
(Minichiello, 2009; Zhang et al., 2012; Cisse and
Checler, 2015; Dines and Lamprecht, 2016). Here we
show that PS1 is necessary for de novo formation of
EFNB1 and BDNF (called here factors)-stimulated com-
plexes of factor receptors (FRs) with the NMDAR and
that formation of these complexes is crucial to factor-de-
pendent neuroprotection. In contrast, PS1 FAD mutants
inhibit factor-dependent neuroprotection, increase neuron-
al vulnerability to ischaemia, and reduce the NMDAR-
mediated excitatory post-synaptic currents at CA1 synap-
ses. Furthermore, expression of PS1 FAD mutants
increases the constitutive levels of the NMDAR–PS1 asso-




Antibodies used in our studies were as follows: for IP
experiments; anti-PS1 (rabbit polyclonal, R222)
(Georgakopoulos et al., 1999), anti-EPHB2 (rabbit poly-
clonal, R407) (Barthet et al., 2013), anti-GLUN1 (mouse
monoclonal; Novus Biologicals, Littleton, CO, USA) and
anti-TRKB (rabbit polyclonal, Abcam; Cambridge, MA,
USA); for western blot (WB) detection; anti-PS1 (rabbit
polyclonal, R222), anti-PS1 (mouse monoclonal, 33B10)
(Huang et al., 2018), anti-EPHB2 (rabbit polyclonal,
Zymed; San Francisco, CA, USA), anti-GLUN1 (mouse
monoclonal; BD Biosciences, San Jose, CA, USA), anti-
GLUN2B (mouse monoclonal; BD Biosciences, San Jose,
CA, USA), anti-ACTIN (mouse monoclonal; Abcam,
Cambridge, MA, USA), anti-TRKB (rabbit polyclonal,
Abcam; Cambridge, MA, USA); for immunofluorescent
experiments; anti-EPHB2 (rabbit polyclonal, Abcam;
Cambridge, MA, USA), anti-GLUN1 (mouse monoclonal;
Biolegend, San Diego, CA, USA) and anti-PS1 (rabbit
polyclonal, R222, affinity purified). Anti PS1-CTF and
anti PS1-NTF: antibodies against the C- or N-terminals
of PS1 respectively. EFNB1-Fc (eB1) ligands prepared as
described (Barthet et al., 2013). Accell non-targeting and
small interfering RNA (siRNA) SMARTpools against
mouse PS1 mRNAs were from Dharmacon (Lafayette,
CO, USA); c-secretase inhibitor (L-685,458) from EMD
Millipore (Billerica, MA, USA); EFNB1-Fc from R & D
Systems (Minneapolis, MN, USA); and BDNF from
Sigma (St. Louis, MO, USA). Clustering of recombinant
mouse EFNB1-Fc ligands and anti-Fc was performed as
described (Barthet et al., 2013).
Primary cortical neuronal cultures
All procedures involving animals were performed in ac-
cordance with the National Institutes of Health (NIH)
guide for the Care and Use of Laboratory Animals and
were approved by the Icahn School of Medicine at
Mount Sinai (New York, NY, USA) Animal Care and
Use Committee. Cortical neuronal cultures from mouse
brains at embryonic day 15.5 were prepared as described
previously (Barthet et al., 2013; Bruban et al., 2015).
Dissociated brain cells were plated onto poly-D-lysine-
coated plates at a density of 1  105 cells/cm2 and
maintained in neurobasal medium that was supplemented
with 2% B27 (Thermo Fisher Scientific), L-glutamine
(0.5 mM) and penicillin/streptomycin (1% vol/vol), and
used at 10–12 days in vitro (DIV). Under these condi-
tions, post-mitotic neurons represent more than 98% of
cultured cells (Huang et al., 2018).
Protein down-regulation by siRNA
Down-regulation of neuronal PS1 by using anti-PS1 small
interfering RNA (siRNA), and control siRNAs
(Dharmacon) was performed as previously described
(Huang et al., 2018). For down-regulation, neurons were
treated at 7 DIV with 1mM of specific siRNA or control
siRNA, and cultures were used for experiments at DIV
10–12. Down-regulation of the proteins of interest was
examined by WB.
Preparation of mouse brain tissue
lysates
Whole tissue lysates were prepared from cortical hemi-
spheres or hippocampi of 4–8 weeks old mice. Briefly,
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brain tissues were homogenized on ice in 1% Triton X-
100 lysis buffer (10 mM HEPES, 2 mM CaCl2, 150 mM
NaCl, 0.02% NaN3; pH 7.4) containing protease and
phosphatase inhibitors. The homogenate was centrifuged
at 14 000 g for 20 min at 4C, and the supernatant was
used as brain tissue lysate for immunoprecipitation
experiments, as described below.
Preparation of synaptosomal
fractions from post-mortem human
brains
We received frontal cortices of post-mortem human brain
carrying wild type (WT) PS1 and PS1 S170F mutation
from the DIAN Human Brain Tissue Bank at
Washington University. Frontal cortices were cut into
smaller pieces on ice. Then, equal amount of tissue was
used to prepare synaptosomal fractions by biochemical
fractionation. Briefly, tissue chunks were homogenized on
ice in 0.32 M sucrose, 4 mM HEPES, pH 7.4, containing
protease and phosphatase inhibitors. After removing the
nuclear fraction by centrifuging at 1000 g for 15 min at
4C, non-synaptic fractions were further centrifuged at
12 000 g at 4 C to obtain the crude synaptosomal frac-
tion. Crude synaptosomal pellets were resuspended and
solubilized in lysis buffer (50 mM Tris, 140 mM NaCl,
0.5% Triton X-100; pH 7.4) containing protease and
phosphatase inhibitors. The resulting solubilized fractions
were used for immunoprecipitation and WB experiments.
Cell survival assay
Briefly, mature cortical neuronal cultures were prepared
and kept in Neurobasal medium supplemented as
described previously; the medium was changed to Hanks’
balanced salt solution (HBSS) (Invitrogen) for 30 min,
and then clustered EFNB1-Fc or BDNF was added for
another 30 min. Glutamate was then added for 3 h before
measurements. For nuclei staining, cells were fixed in 4%
paraformaldehyde for 20 min at room temperature and
stained with Hoechst 33342 for 10 minutes. Stained nu-
clei were then observed under a fluorescence microscope
using ultraviolet illumination and counted according to
manufacturer’s instructions (Sigma). Cells were kept and
maintained, and numbers of viable neurons were deter-
mined as described (Barthet et al., 2013). Clustered
EFNB1-Fc was prepared as reported (Barthet et al.,
2013).
Immunoprecipitations
After exposure of the neuronal cultures to the conditions
as indicated in the figure legends, total cellular extracts
from were prepared in 1% Triton X-100 lysis buffer
(10 mM HEPES, 2 mM CaCl2,150 mM NaCl, 0.02%
NaN3; pH 7.4) containing protease and phosphatase
inhibitors following the method as described previously
(Al Rahim et al., 2013). Fixed amount of proteins were
subjected to immunoprecipitation by incubating overnight
with indicated antibodies at 4C. Then, 25 ll of protein
A/G-agarose conjugated beads was added to each sample
and incubated for 2–4 more hours at 4C. Beads were
washed two times with lysis buffer and once with HEPES
buffer containing protease and phosphatase inhibitors.
Proteins were subsequently eluted from the beads by boil-
ing in 1 SDS sample buffer for 5 min. Eluted proteins
were separated on SDS-PAGE gels, transferred to polyvi-
nylidene difluoride (PVDF) membrane (Millipore),
blocked with 5% milk, labelled with the indicated pri-
mary and horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies, and visualized with West Pico or
Dura Chemiluminescent reagents (Thermo Scientific). We




For detection of surface EPHB2/GLUN1 clusters, neurons
were treated with EFNB1-Fc or Fc for 1 h prior to incu-
bation with primary antibodies against EPHB2 (1:100,
Rabbit polyclonal) and GLUN1 (1:50, Mouse monoclo-
nal) for 8 min in the incubator. After washing with PBS
gently once, neurons were fixed with 4% paraformalde-
hyde and 2% sucrose for 8 min. After washing with PBS
three times, cells were blocked with 1% bovine albumin
and 0.2% cold-water fish gelatine for 1 h before incuba-
tion with secondary antibodies (Goat anti-rabbit IgG
with Alexa Fluor 488 conjugates, and goat anti-mouse
IgG with Alexa Fluor 568 conjugates) for 45 min at
room temperature. After washing with PBS three times,
the coverslips were mounted on slides with Vectashield
mounting media with DAPI (Vector Laboratories). For
immunohistochemistry, adult mice were euthanized and
perfused transcardially with PBS followed by 4% PFA.
The brains were removed and post-fixed overnight in 4%
PFA, soaked in 30% sucrose for 3 days at 4C. The
brains were later embedded in optimal cutting tempera-
ture (OCT) compound and sliced at 20 lm sections on a
cryostat. The brain slices were mounted on slides and
blocked with 10% heat inactivated goat serum (HIGS) in
PBS for 1 h, stained with anti-PS1 and aniti-GLUN1 anti-
bodies overnight at 4C. The following day, the slides
were washed, stained with corresponding secondary anti-
bodies, and mounted.
Electrophysiology
For slice preparation, WT and PS1 FAD (M146V) adoles-
cent mice of either sex, 21–25 days old, were deeply
anaesthetized with isoflurane and decapitated. Brains
were rapidly removed and placed into ice-cold sucrose-
artificial cerebrospinal fluid (sucrose-aCSF) consisting of
(in mM): 233.7 sucrose, 26 NaHCO3, 3 KCl, 8 MgCl2,
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0.5 CaCl2, 20 glucose and 0.4 ascorbic acid. Coronal
hippocampal slices (350 mm) were cut with a Leica
VT1000S vibratome and allowed to equilibrate in record-
ing aCSF at room temperature for 1 h before being
transferred to the recording chamber. The aCSF was
composed of (in mM): 117 NaCl, 2.5 KCl, 1.2 MgSO4,
2.5 CaCl2, 1.2 NaH2PO4, 24.9 NaHCO3 and 11.5 glu-
cose. During recording, slices were maintained at 31C
and perfused (1.5 ml/min) with oxygenated aCSF (95%
O2–5% CO2) in an immersion chamber containing the
GABAA receptor antagonist gabazine (GBZ; 10 mM) and
an (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid) AMPA receptor antagonist NBQX (10 mM).
Whole-cell patch-clamp recordings
An upright epifluorescence microscope (BX50WI;
Olympus) was used to visualize CA1 pyramidal neurons
in hippocampus. Whole-cell recordings were performed
using glass borosilicate capillaries pulled on a P-87
micropipette puller (Sutter Instruments). The resistance of
pipettes used for recordings was 3–5 MX. To record
pharmacologically isolated NMDA receptor (NMDAR)
EPSCs, electrodes were filled with caesium based intracel-
lular solution containing (in mM): 120 Cs-methanesulfo-
nate, 10 HEPES, 0.5 EGTA, 8 NaCl, 5 TEA-Cl, 4 Mg-
ATP, 0.4 Na-GTP and 10 phosphocreatine. Osmolarity
was adjusted to 285 mOsm and pH to 7.3. All record-
ings were made in voltage clamp mode using a
Multiclamp 700B amplifier (Molecular Devices).
Analogue signals were low-pass filtered at 2 kHz and
digitized at 5 kHz with the use of a Digidata-1440A
interface and pClamp10 software (Molecular Devices).
Gigaseal and additional access to the intracellular neuron-
al compartment was achieved in voltage clamp where
each cell was held at the holding potential of -70 mV.
Cells with series resistance >25 MX were discarded. To
study isolated NMDA currents, the holding potential was
slowly changed to þ40 mV without compensating series
resistance in the presence of 10 mM NBQX and 10 mM
GBZ. Pharmacologically isolated NMDAR EPSCs were
then evoked at Schaffer collateral-CA1 synapses by pre-
synaptic stimuli of increasing intensity (50-500 mA). We
applied five stimuli (10 s apart) per step of current inten-
sity. Each current step increased by 50 mA. All drugs used
in these experiments were purchased from Tocris.
Middle cerebral artery occlusion
(MCAO), and measuring neuronal
viability by stereology
Experiments were carried out in adult male mice weigh-
ing 18–33 g. Animals were housed under controlled diur-
nal lighting conditions and allowed access to food and
water ad libitum until the day of the experiment.
Anaesthesia was induced by intraperitoneal injection of a
mixture of ketamine (120 mg/kg) and xylazine (20 mg/kg).
Depth of anaesthesia was assessed by toe pinch. Focal
cerebral ischaemia was induced using an occluding sili-
con-coated intraluminal suture as previously described
(Yenari et al., 1996; Kim et al., 2004). Briefly, following
an adapted Koizumi MCAO method, after midline neck
incision, the common and external carotid arteries were
isolated and ligated with silk suture (Brain tree Inc.). Silk
sutures were temporarily placed on the internal carotid
artery and common carotid artery. After 50 min, the su-
ture was withdrawn, and surgical incisions were closed.
Deltaphase isothermal pads (Brain tree Inc.) were used to
keep the animals’ body temperature stable post-anaesthe-
sia, during the surgical procedure and until fully recov-
ered. Successful application of MCAO was determined by
Laser Doppler flowmetry. Only mice in which cerebral
blood flow was dropped to >70% of the baseline (before
MCAO) after the occlusion were used for experiments.
An additional criterion was that the infarcted area vol-
ume should be 25–45% of the ipsilateral hemisphere vol-
ume. After occluding for transient focal cerebral
ischaemia for 50 min, brains were isolated and sectioned
30 days later. Brain sections were stained with anti-NeuN
antibody (abcam), and NeuNþ cells were counted with
stereo investigator software. Number of NeuNþ neurons
in the MCAO-induced cortex lesion area was normalized
to number of NeuNþ neurons in the contralateral side of
each section.
Imaging and analysis
Fluorescent images of neurons in culture were taken
using Leica SP5 DMI Confocal microscope with the same
background and parameters. Neurons (two per field)
were selected at random and analysed in each microscop-
ic field (three fields in each condition). Single channel
Images were analysed using MetaMorph Image Analysis
software. Co-localization was analysed using ImageJ soft-
ware with JACoP plugin (Dunn et al., 2011) using
Manders’ co-localization coefficients, M1 and M2. M1 is
defined as the fraction of overlapping pixels in total pix-
els of EPHB2, while M2 is defined as the fraction of
overlapping pixels in total pixels of GLUN1. Images of
the diffuse background fluorescence were thresholded,
and clusters were defined as regions with a higher than
2-fold intensity increase in diffuse intensity. Each experi-
mental manipulation was performed in each genotype at
least three times. The brain sections were imaged on a
Leica SP5 DMI confocal microscope under 100 oil lens
with stack images using optimal step. For analysis of
PS1/GLUN1 co-localization, Metamorph software avail-
able in Mount Sinai imaging core was used. In each
batch of the images, background fluorescence was first
subtracted by measuring a blank area, and then a thresh-
old was set for each channel (consistent among all images
in one batch), after which the area of overlap (co-local-
ization) between two channels was calculated.
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Statistical analyses
Data are expressed as means 6 SEM. Statistical signifi-
cance of differences among groups was determined by
one-way analysis of variance followed by the post hoc
test described in individual figure legends, or with a two-
tailed paired t-test. Distribution of the data was assumed
to be normal, but this was not formally tested. No statis-
tical methods were used to predetermine sample sizes. To
evaluate statistical significance of treatments, two-tailed
paired t-tests were performed against the value of the un-
treated basal condition (*P< 0.05; **P< 0.01;
***P< 0.001). For EPHB2/GLUN1 clusters, statistics
were analysed using two-tailed unequal variance unpaired
Student’s t-test for 2-group comparison affected by 1 fac-
tor. Statistical significance was performed with GraphPad
Prism 6 (GraphPad Software, La Jolla, CA, USA). For
electrophysiology data, offline analysis was performed
using Clampfit software (Molecular Devices).
Comparisons between groups were carried out by two-
way ANOVA, with Bonferroni post hoc testing for mul-
tiple comparisons using OriginPro10.1 software.
Differences were considered significant at values of
P 0.05. All results are presented as means 6 SEM.
Data availability
The authors confirm that all the data supporting the find-
ings of this study are available within the article and its
Supplementary material. Raw data will be shared by the
corresponding author upon request.
Results
The EFNB1-stimulated association
of EPHB2 with GLUN1 depends on
PS1 and is crucial to
neuroprotection
Literature shows that EFNB1 and BDNF (factors) stimulate
the association of their receptors, EPHB2 and TRKB re-
spectively, with the GLUN1 subunit of the NMDA receptor
(Dalva et al., 2000; Suen et al., 1997; Stucky et al., 2016),
and we obtained data that these factors stimulate similar
complexes in mouse cortical neuronal cultures
(Supplementary Figs 1, 2). In addition, we reported that the
neuroprotective functions of both EFNB1 and BDNF de-
pend on PS1 (Barthet et al., 2013), a protein known to
play crucial roles in Alzheimer disease neurodegeneration
(Russo et al., 2000). To examine whether PS1 plays a role
in the association of EPHB2 with NMDAR, we treated cor-
tical neuronal cultures from WT (PS1þ/þ) mice or from
PS1 hemizygous (PS1þ/) or homozygous (PS1/)
knockout (KO) mice with EFNB1 (eB1) and probed for the
formation of EPHB2–GLUN1 complexes. We found that
the eB1-dependent stimulation of the EPHB2–GLUN1
complex was strongly inhibited in PS1 hemizygous
(PS1þ/) and was undetectable in PS1 null (PS1/) neu-
rons (Fig. 1A and B). Furthermore, acute down-regulation
of PS1 by means of anti-PS1 siRNA (Bruban et al., 2015),
also decreased the eB1-induced association of EPHB2 with
GLUN1 (Fig. 1C). Genetic reduction or deletion of the PS1
gene had no effect on the cellular levels of EPHB2 and
GLUN1 proteins (Fig. 1A and C, lower panels). Together,
our data show that PS1 is necessary for the eB1-induced as-
sociation of EPHB2 with GLUN1.
It is known that PS1 has c-secretase-dependent and in-
dependent functions (Wolfe et al., 1999; Baki et al.,
2001; Kallhoff-Munoz et al., 2008) and that EPHB2 is
proteolytically processed by c-secretase (Litterst et al.,
2007). We thus asked whether the EPHB2 association
with GLUN1 is regulated by this aspartyl protease. Our
data (Supplementary Fig. 3A) show that c-secretase inhib-
itors have no significant effect on the eB1-induced associ-
ation of EPHB2 and GLUN1, a result in agreement with
an earlier report that c-secretase does not modulate the
eB1-dependent neuroprotection (Barthet et al., 2013).
Since PS1 is required for both, the eB1-dependent neuro-
protection (Barthet et al., 2013) and the eB1-induced
EPHB2–GLUN1 association described here, we asked
whether the eB1 stimulation of the EPHB2–GLUN1 com-
plex is critical to the neuroprotective activity of eB1.
Based on reports that the eB1-stimulated complex of
EPHB2 and GLUN1 is mediated by the extracellular
domains of these proteins (Dalva et al., 2000), we con-
structed peptide exEPHB2 containing the extracellular re-
gion of EPHB2 (residues Ser212-Lys540) minus the
N-terminal eB1-binding domain. We reasoned that, fol-
lowing eB1 treatment, exEPHB2 would compete with en-
dogenous EPHB2 for binding to GLUN1 leading to
reduced stimulation of the neuronal EPHB2–NMDAR
complex and attenuated neuroprotection. Indeed, Fig. 1D
shows that exEPHB2 strongly reduces the eB1-induced
association of EPHB2 with GLUN1. Furthermore, in
agreement with our hypothesis, exEPHB2 inhibits the
eB1-dependent neuroprotection against glutamate excito-
toxicity, while bovine serum albumin (BSA), a protein of
comparable size to that of exEPHB2, had no effect on
neuroprotection (Fig. 1E). Together, our data show that
inhibition of the eB1-stimulated association of EPHB2
with GLUN1 reduces the eB1-stimulated neuroprotection,
indicating that the inducible EPHB2–GLUN1 complex
plays pivotal roles in the eB1-dependent neuroprotection.




PS1 mutations are the most common cause of FAD
(Sherrington et al., 1995), (http://www.alzforum.org/muta
tions), and we showed that PS1 is also essential to the
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neuroprotective functions of the EFNB1/EPHB2 and BDNF/
TRKB ligand–receptor systems (Barthet et al., 2013). We
thus asked whether PS1 FAD mutants might affect the neu-
roprotective functions of EFNB1 (eB1) and BDNF. To test
this, we used cortical neuronal cultures from two independ-
ently constructed PS1-FAD mutant knock-in (KI) mice, one
expressing human FAD mutant allele PS1 M146V (Guo
et al., 1999; Nikolakopoulou et al., 2016) and the other
expressing FAD allele I213T (Nakano et al., 1999; Baki
et al., 2004; Nikolakopoulou et al., 2016). In these mod-
els, an endogenous PS1 allele is replaced by an exogen-
ous mutant PS1 allele that remains under the control of
endogenous gene expression promoters and shows physio-
logical levels of expression (see input panels of Figs 2B,
4A and 7D). Importantly, these KI mice have a similar
genotype as PS1 FAD patients and should be free of
Figure 1 Role of PS1 on EFNB1-stimulated EPHB2-GLUN1 association and neuroprotection. Primary cortical neuronal cultures
prepared from WT (PS1 þ/þ), PS1 hemizygous (PS1 þ/) r PS1 homozygous knock out (PS1 /) mouse embryonic brains, were stimulated at
10 DIV with EFNB1-Fc (eB1, 2 mg/ml) or Fc for 60 min, lysed and immunoprecipitated (IPed) with anti-EPHB2 antibody. (A) Obtained
immunoprecipitates (IPs) were then probed on WBs with anti-GLUN1 or anti-EPHB2 antibodies (upper panel). Input: neuronal lysates used in
this IP experiment were immunoblotted with antibodies against GLUN1, EPHB2, PS1-CTF and ACTIN as shown in figure (lower panel). NIS ¼
non-immune serum. (B) Graphs show quantification of EPHB2-GLUN1 complexes IPed as above. Data are mean 6 SEM. *P< 0.05 versus Fc,
two-tailed paired t-test, n¼ 3. (C) Down-regulation of PS1 using PS1 siRNA decreases the EFNB1-dependent complex between EPHB2 and
GLUN1. Scrambled siRNA was used as control. (D) ExEPHB2 inhibits the EFNB1-induced association of EPHB2 with GLUN1. Neuronal cultures
were pretreated for 1 h with either exEPHB2 or BSA (50 nM) followed by EFNB1 (eB1) stimulation for 1 h. Neurons were lysed afterwards, and
extracts were IPed with anti-GLUN1 followed by WB with anti-EPHB2 and anti-GLUN1 antibodies. All detected antigens of co-IPs and Inputs
are indicated at left of figures. (E) Extracellular peptide, exEPHB2, abolishes EFNB1 mediated neuroprotection from glutamate excitotoxicity.
WT primary cortical neuronal cultures were pretreated for 1 h as indicated in the figure, and then challenged with glutamate (G) at 50 lM for
3 h. Neuronal survival was then determined as described in Materials and methods section. Percent survival is normalized to the survival of the
culture treated with glutamate (Glu) alone (dotted horizontal line). EFNB1 rescues neurons from excitotoxicity in the absence (third bar from
left) but not in the presence of peptide ex-EPHB2 (50 nM; 4th bar). BSA ¼ bovine serum albumin. Data are mean 6 SEM. *P< 0.05, **P< 0.01;
one-way ANOVA with Tukey’s post hoc test, n¼ 3–5. Cell survival in the presence of glutamate is set at 100%.
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potential artefacts reported in protein overexpression
Alzheimer disease models (Saito et al., 2016). We
observed that expression of PS1 FAD mutant alleles in ei-
ther heterozygous (KI/WT) or homozygous (KI/KI) state
inhibits the neuroprotective functions of both eB1 and
BDNF following glutamate excitotoxicity (Fig. 2A).
Neuronal cultures from both KI mouse models yielded
similar results suggesting that PS1 FAD mutations may
have dominant negative effects on the neuroprotective
activity of brain neurotrophins. In contrast, the neuropro-
tective functions of basic fibroblast growth factor (bFGF),
were not affected by FAD mutant PS1M146V
(Supplementary Fig. 4) or by mutant PS1I213T (data not
shown). Together, our data indicate that FAD mutants
compromise the neuroprotective activity of specific neuro-
protective factors. Importantly, our data that the neuro-
protective activities of BDNF and eB1 decrease in
neurons expressing FAD mutations support the theory
Figure 2 Effects of PS1 FAD mutants on factor-dependent neuroprotection, and EPHB2-GLUN1 association. (A) Cortical
neuronal cultures prepared from E15 mouse embryos wild-type (WT), heterozygous (M146V/WTand I213T/WT) or homozygous (M146V/
M146V and I213T/I213T) for PS1 FAD alleles M146V or I123Twere cultured in 24-well plates and 10–12 days later were treated with either
EFNB1-Fc (eB1, 2 mg/ml) or BDNF (50 ng/mL) for 30 min. Cultures were then treated with 50 lM glutamate (Glu) for 3 h. Neuronal viability was
quantified by counting healthy nuclei stained with Hoechst kit 33342 as described (Barthet et al., 2013). Percent survival of each neuronal
genotype is normalized to the survival of the same culture treated with glutamate alone (dotted horizontal line). Data are mean 6 SEM.
*P< 0.05, two-tailed paired t-test, n¼ 4. Cell survival in the presence of glutamate is set at 100%. (B) Cortical neuronal cultures from WT,
heterozygous (KI/WT) and homozygous (KI/KI) for PS1 FAD KI mutant M146V or I213T mouse embryonic brains were treated with eB1 or Fc
for 60 min, lysed and IPed with anti-EPHB2 antibody, then immunoblotted with anti-GLUN1 and anti-EPHB2 antibodies, respectively. The input
of the IP experiment is also shown in the lower panel. (C) Graphs illustrate fold change of GLUN1 IPed with EPHB2 following eB1 stimulation.
Experiments were repeated four times. Data are mean 6 SEM. *P< 0.05, eB1 versus Fc in WT; #P< 0.05 and ##P< 0.01 FAD Fc control versus
WT Fc control, two-tailed paired t-test, n¼ 4.
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that FAD mutants may contribute to neurodegeneration
by reducing neuroprotective activities of brain neuro-
trophic factors.
Based on our data that the eB1-induced association of
EPHB2 and GLUN1 plays crucial roles in the eB1-de-
pendent neuroprotection and that PS1 FAD mutants re-
duce this activity, we next asked whether FAD mutants
also affect the eB1-induced association between EPHB2
and GLUN1. We found that unlike WT neurons that re-
spond to eB1 by increasing the EPHB2–GLUN1 complex
(Dalva et al., 2000; also Fig. 1A, PS1þ/þ, and
Supplementary Fig. 1), neurons expressing PS1 FAD mu-
tant M146V or I213T in either heterozygous (KI/WT) or
homozygous (KI/KI) states failed to respond to eB1 treat-
ment by stimulating the EPHB2–GLUN1 complex
(Fig. 2B). To our surprise, however, we observed that
neurons expressing PS1 FAD mutants contained increased
levels of the constitutive EPHB2–GLUN1 complex com-
pared to WT neurons (Fig. 2B and C), although total ex-
pression of the interacting proteins were comparable
among different genotypes (Fig. 2B, lower panel). It has
been shown that the eB1-stimulated association of
EPHB2 with GLUN1 causes increased co-clustering of
these two proteins on neuronal surfaces (Dalva et al.,
2000). We thus employed quantitative immunocytochem-
istry to ask whether PS1 FAD mutants also inhibit the
eB1-stimulated co-clustering of these two proteins at the
cell surface while increasing the constitutive levels of
co-clustered EPHB2 and GLUN1. Figure 3 shows that
compared to WT neurons, neurons expressing PS1 FAD
mutant M146V in heterozygous (KI/WT) or homozygous
(KI/KI) state, had increased levels of constitutive EPHB2–
GLUN1 co-clustering. However, in contrast to WT
neurons, eB1 treatment failed to stimulate further the as-
sociation of these proteins on the surface of PS1 FAD
mutant-expressing neurons (Fig. 3A and B). These results
are in agreement with our co-IP data and support the
conclusion that PS1 FAD mutants upregulate the constitu-
tive EPHB2–GLUN1 complex while rendering it unre-
sponsive to eB1. To further test our in vitro findings, the
EPHB2–GLUN1 complex was immunoprecipitated from
mouse brain hippocampi. In agreement with the data
obtained in primary neuronal cultures, brains heterozy-
gous (KI/WT) or homozygous (KI/KI) for PS1 FAD mu-
tant M146V or I213T contained significantly higher
amounts of the EPHB2–GLUN1 complex than brains
expressing WT PS1 although total amounts of these pro-
teins were comparable in all brains (Fig. 4A and B).
PS1 FAD mutations decrease the
EFNB1-stimulated association of
GLUN1 with PS1
Since PS1 has been found in complexes with GLUN1
(Saura et al., 2004), our finding that the EFNB1-stimu-
lated EPHB2–GLUN1 complex depends on PS1 (Fig. 1A)
suggested that EFNB1 (eB1) may also stimulate the asso-
ciation of PS1 with GLUN1. Indeed, Fig. 5A shows that
eB1 treatment significantly increases the PS1–GLUN1
complex in primary neuronal cultures from WT mice. We
also found that eB1 stimulates the PS1–GLUN2B com-
plex supporting the conclusion that eB1 stimulates the
PS1 association with the NMDAR. Furthermore, cortical
neuronal cultures expressing FAD mutants in either het-
erozygous or homozygous state show no significant
stimulation of the PS1–GLUN1 complex in response to
eB1 (Fig. 5B), suggesting dominant negative effects of
FAD mutants on the eB1-dependent stimulation of this
complex. In addition, neuronal cultures expressing PS1
FAD mutants (KI/WT or KI/KI) showed higher constitu-
tive levels of the PS1–GLUN1 complex than WT neurons
(Fig. 5B). Similarly, mouse brains expressing mutant PS1
had increased amounts of the PS1–GLUN1 complexes
(Fig. 5C) and immunohistochemistry experiments indi-
cated increased co-localization of PS1 with GLUN1 in
mouse brain cortex of PS1 FAD mutant-expressing brains
compared to WT brains (Fig. 6A and B). Together, our
data indicate higher levels of constitutive PS1–GLUN1 as-
sociation in FAD mouse brains compared to WT brains.
We next asked whether increased association of mutant
PS1 with GLUN1 in mouse brains could be reproduced
in a non-neuronal system. To this end, HEK293 cells
were co-transfected with plasmids expressing GLUN1 and
WT or mutant PS1 (M146V or I213T). We found that
GLUN1 and PS1 coimmunoprecipitate, indicating that
GLUN1 and PS1 form a complex when expressed in
HEK293 cells. While both WT and mutant PS1 associ-
ated with GLUN1, we observed a clear trend of mutant
PS1 being associated more with GLUN1 (Supplementary
Fig. 5, left upper panel). However, the increase in the
GLUN1 association with PS1 mutants compared to WT
proteins failed to reach significance due to variations
associated with the overexpressions of WT and mutant
proteins (Supplementary Fig. 5, right panel). In addition,
we cannot exclude the possibility that neuronal factors
absent from HEK cells may affect the stability of the mu-
tant PS1–GLUN1 complex.
To examine any differences in the stability of the PS1–
GLUN1 complex formed in WT neurons and in neurons
expressing PS1 FAD mutants, we tested the rate of dissoci-
ation of these complexes in neuronal cultures. As expected,
eB1 increased the association of GLUN1 with WT PS1
(Fig. 6C) and the levels of the stimulated PS1–GLUN1
complex decreased following withdrawal of eB1. In con-
trast, consistent with data in Fig. 3B, eB1 was unable to
stimulate the PS1–GLUN1 complex in neurons expressing
mutant PS1, and the levels of the constitutive complex did
not decline following withdrawal of eB1 (Fig. 6D).
Together, these data indicate that PS1 FAD mutations sta-
bilize the PS1–GLUN1 association independent of eB1.
Next, we examined the GLUN1–PS1 protein complexes
in human post-mortem brains. We obtained frontal corti-
ces from non-demented post-mortem human brains
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carrying WT PS1 (control brains) and from two individu-
als each afflicted by FAD and each heterozygous for mu-
tant PS1S170F (mutant brains) from the DIAN Human
Brain Tissue Bank at Washington University. Initial
efforts to co-IP the PS1–GLUN1 complex using total
homogenates of post-mortem brain samples were unsuc-
cessful. We then fractionated our samples to prepare
crude synaptosomal membrane fractions that were then
used to co-precipitate PS1 and GLUN1 from control and
mutant brains. In agreement with our data in mouse
brain, we found that brain tissue from the two individu-
als each expressing mutant PS1S170F showed higher lev-
els of the GLUN1–PS1 complex compared to control
brain tissue from non-carriers (Fig. 6E). It is important to
note that the two brain tissue samples each carrying mu-
tant PS1S170F are from a male and a female sibling.
Additional brain samples from FAD patients carrying dif-
ferent PS1 FAD mutations, including A79V and T245P,
did not show increased level of this protein complex. It is
unclear whether our inability to detect increased PS1–
GLUN1 complex in other human tissues expressing dif-
ferent FAD mutants is related to the quality of the post-
mortem brain tissue or an indication that the increase of
the PS1–GLUN1 complex is mutation specific.
BDNF increases neuroprotection by
inducing a PS1-dependent
TRKB–GLUN1 complex
Previous studies show that exogenous BDNF protects neu-
rons against glutamate excitotoxicity (Mattson et al., 2002;
Figure 3 PS1 FAD mutants modulate EPHB2 co-clustering with GLUN1 on neuronal surface. (A) Cortical neuronal cultures from
WTand PS1 FAD (M146V) mouse embryonic brains either heterozygous (M146V KI/WT) or homozygous (M146V KI/KI) were stimulated with
eB1 or Fc for 60 min, followed by live-labelling with anti-EPHB2 and anti-GLUN1 antibodies to detect clusters of the receptors on cell surface
and their co-localization. In all cases, green indicates EPHB2 staining, red indicates GLUN1 staining, and blue is DAPI nuclear staining. White
arrow indicates both single channel immunostaining and co-localized clusters. Scale bar, 5 mm. (B) Graphs showing percent change of co-
localization of EPHB2 and GLUN1 over Fc treated WT group by following Mander’s co-localization coefficients. Data are mean 6 SEM.
**P< 0.01, eB1 versus Fc in WT; ###P< 0.001 FAD Fc control versus WT Fc control, Mander’s co-localization coefficients, n¼ 9–7.
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Almeida et al., 2005; Barthet et al., 2013), and that,
similar to EFNB1 (eB1), the ability of BDNF to protect
neurons from excitotoxicity depends on PS1 (Barthet
et al., 2013). Furthermore, BDNF stimulates the associ-
ation of its receptor TRKB with the GLUN1 subunit of
NMDAR (Stucky et al., 2016), and we obtained similar
data that BDNF stimulates the TRKB–GLUN1 interaction
in primary neurons (Supplementary Fig. 2). We thus
asked whether PS1 is also required for the BDNF-stimu-
lated association between TRKB and NMDAR.
Figure 7A shows that genetic deletion of PS1 inhibits the
BDNF-induced TRKB–GLUN1 complex but has no effect
on the total amounts of TRKB or GLUN1 (Fig. 7A,
lower panel). Similarly, acute down-regulation of PS1
with siRNA as in Fig. 1C also caused a dramatic reduc-
tion of the BDNF-induced association of TRKB with
GLUN1 (Fig. 7B). Together, our data show that PS1 is
required for BDNF-stimulated association of TRKB with
GLUN1.
Since PS1 is also necessary for the BDNF-dependent
neuroprotection (Barthet et al., 2013), we asked whether
the BDNF-induction of the TRKB–GLUN1 complex is
critical to its neuroprotection activity. To test this ques-
tion, we used methods similar to the one we applied to
EFNB1–EPHB2 system above. Since it is currently unclear
what TRKB sequence mediates the TRKB–GLUN1 inter-
action, we reasoned that, similar to the eB1-stimlated
EPHB2–GLUN1 complex, the extracellular regions of
TRKB and GLUN1 are involved in the BDNF-stimulated
TRKB–GLUN1 association. This possibility is also sup-
ported by data that these two proteins form a complex
stimulated by exogenous BDNF (Stucky et al., 2016, and
Fig. 7A). To test this hypothesis, we constructed a pep-
tide comprising the N-terminal extracellular region of
mouse GLUN1 (exGLUN1; Arg19-Ser560). We reasoned
that following BDNF treatment; exGLUN1 would com-
pete with endogenous GLUN1 for the TRKB binding
site(s) leading to decreased association of TRKB with
Figure 4 PS1 FAD mutants affect EPHB2 association with GLUN1 in mouse brains. (A) Four-week-old WT, heterozygous (KI/WT)
and homozygous (KI/KI) for PS1 FAD mutant M146V or I213T mouse brain hippocampi were homogenized in Hepes buffer containing 1% Triton-
X 100. After centrifugation, total lysates were IPed with anti-EPHB2 antibody, then immunoblotted with anti-GLUN1 or anti-EPHB2 antibodies,
respectively. The neuronal lysates used in the IP experiment were immunoblotted with antibodies against GLUN1, EPHB2 and ACTIN (input,
lower panel). (B) Graphs display fold of GLUN1 immunoprecipitated with EPHB2. Data are mean 6 SEM. *P< 0.05 versus WT, one-way
ANOVA with Tukey’s post hoc test, n¼ 3.
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GLUN1 and attenuated neuroprotection. In agreement
with our hypothesis, exGLUN1 caused a significant de-
crease in the neuroprotective activity of BDNF against
excitotoxicity; but exEPHB2, a peptide that inhibits the
eB1 neuroprotection, had no effect on the BDNF neuro-
protection (Fig. 7C, upper panel), supporting the specifi-
city of exGLUN1 in attenuating BDNF neuroprotection.
Furthermore, Fig. 7C (lower panel), shows that
exGLUN1 also decreases the BDNF-stimulated association
of TRKB and GLUN1. Thus, attenuation of neuroprotec-
tion by peptide exGLUN1 was concomitant with the re-
duction of the inducible TRKB–GLUN1 complex in
neurons treated with this peptide, suggesting that interfer-
ence with the de novo complex formation has important
consequences for BDNF neuroprotection. Together, our
data indicate that the BDNF-induced association of
TRKB and GLUN1 is crucial to the BDNF-dependent
neuroprotection.
PS1 FAD mutants decrease
BDNF-stimulated association of
GLUN1 with TRKB and PS1
The BDNF–TRKB ligand–receptor system has been impli-
cated in Alzheimer disease (Salehi et al., 1996, Holsinger
et al., 2000), and we asked whether PS1 FAD mutants
which decrease BDNF neuroprotection (Fig. 2A), might
also interfere with the ability of BDNF to stimulate the
TRKB-GLUN1 complex. Figure 7D shows that although
BDNF increases this complex in WT neurons, it has a
reduced effect on the TRKB–GLUN1 complex in neurons
expressing PS1 FAD mutants. However, unlike the consti-
tutive EPHB2–GLUN1 complex which increases in FAD
mutants (Figs 2B and C, 3 and 4), there was no signifi-
cant difference in the constitutive amounts of the TRKB–
GLUN1 complex between WT and PS1 FAD neuronal
cultures (Fig. 7D; NT lanes), suggesting that FAD
Figure 5 Effects of EFNB1 and PS1 FAD mutants on NMDAR interactions with PS1. (A) Cortical neuronal cultures were stimulated
with EFNB1 (eB1) or Fc for 60 min. After stimulation, cells were lysed and IPed with anti-PS1 NTF antibody, then immunoblotted with anti-
GLUN1 and anti-GLUN2B antibodies. PS1 NTF (PS1) was detected under the same condition with unboiled samples. Graphs show fold change
of GLUN1 immunoprecipitated with PS1 following eB1 stimulation (right panel). Experiments were repeated at least three times. Data are mean
6 SEM. *P< 0.05 versus Fc, two-tailed paired t-test, n¼ 3. The inputs are shown in the lower panel. (B) Cortical neuronal cultures from WT,
heterozygous (KI/WT) and homozygous (KI/KI) for PS1 FAD KI mutant M146V or I213T mouse embryonic brains were treated with eB1 or Fc
for 60 min, lysed and IPed with anti-PS1 NTF antibody, then immunoblotted with anti-GLUN1. PS1 was detected under the same condition with
unboiled samples. PIS ¼ pre-immune serum. (C) Three-month-old WTand PS1 FAD (M146V and I213T) KI heterozygous (KI/WT) or
homozygous (KI/KI) mouse brain cortices were homogenized in Hepes buffer containing 1% Triton-X 100. After centrifugation, total lysates
were IPed with anti-PS1 NTF antibody, then immunoblotted with anti-GLUN1 and anti-GLUN2B antibodies. PS1 was detected under the same
condition with unboiled samples.
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Figure 6 PS1 FAD mutants affect GLUN1 co-localization with PS1, and modulate PS1-GLUN1 complex stability. (A, B) Co-
localization of PS1 and GLUN1 in mouse cortex was detected using double fluorescence staining with antibodies against PS1 (green) and GLUN1
(red), followed by analysis with metamorph. Increased overlay of PS1 and GLUN1 staining (yellow) were detected in PS1 FAD mutant M146V
heterozygous (KI/WT) and homozygous (KI/KI) mice. White arrow indicates both single channel immunostaining and co-localization. Scale bar
1 mm. One-way ANOVA followed by Tukey’s multiple comparison test was used for statistical analyses. **P< 0.01, ***P< 0.001 versus WT,
n¼ 7–9. (C, D) Cortical neuronal cultures from WT, and heterozygous for PS1 M146V mutant (M146V/WT) mouse embryonic brains were
treated with eB1 for 1 h in neurobasal media followed by withdrawal of the ligand, and replacing the media with fresh neurobasal. Cells were
thereafter collected and lysed at post-eB1 withdrawal hours as indicated. Neuronal lysates were used for IP experiments as depicted in the
figure. No withdrawal means eB1 ligand remained in the media the entire experimental period. (E) Frontal cortices from normal (control) and
FAD human brains carrying PS1 S170F mutant (PS1 FAD) were used to isolate crude synaptosomal membrane fractions. The fractions were IPed
with anti-PS1 NTF antibody. WB experiments showed constitutively higher amount of PS1-GLUN1 complexes in FAD brains than control brains.
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Figure 7 Role of PS1 on BDNF-stimulated TRKB-GLUN1 association and neuroprotection; and effects of PS1 FAD mutants
on GLUN1 interactions with TRKB and PS1. Primary cortical neurons prepared from WT (PS1 þ/þ), PS1 hemizygous (PS1 þ/) or PS1
homozygous knock out (PS1 /) mouse embryonic brains, were stimulated with BDNF (50 ng/ml) or no treatment (NT) for 30 min, lysed and
IPed with anti-TRKB antibody. (A) Obtained IPs were then probed on WB with anti-GLUN1 or anti-TRKB antibodies (upper panel). Graphs
show quantification of TRKB-GLUN1 complexes IPed as above. Data are mean 6 SEM. **P< 0.01, one-way ANOVA with Tukey’s post hoc test,
n¼ 3 (right panel). Input: Neuronal lysates used in this IP experiment were immunoblotted with antibodies against GLUN1, TRKB, PS1-CTF and
ACTIN as shown in figure (lower panel). NI IgG ¼ non-immune IgG. (B) Down-regulation of PS1 using PS1 siRNA decreases the BDNF-
stimulated complex between TRKB and GLUN1. Scrambled siRNA was used as control. (C) (upper panel) Extracellular peptide, exGLUN1,
abolishes BDNF mediated neuroprotection from glutamate excitotoxicity. Primary cortical neuronal cultures were pretreated for one hour as
indicated in the figure, and then challenged with glutamate (Glu) at 50 lM for 3 h. Neuronal survival was then determined as described in
Materials and methods section. BDNF rescues neurons from excitotoxicity in the absence (3rd bar from left), but not in the presence of peptide
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mutations affect differently these two complexes. We next
examined the effects of BDNF on the PS1–GLUN1 com-
plex in WT and FAD mutant-expressing neurons. We
observed that BDNF increased the PS1–GLUN1 com-
plexes in WT neuronal cultures (Supplementary Fig. 6)
but, similar to eB1, neurons expressing PS1 FAD mutants
in heterozygous or homozygous states showed no signifi-
cant stimulation of the PS1–GLUN1 complex in response
to BDNF (Fig 7E), indicating dominant negative effects of
FAD mutants on the BDNF-dependent stimulation of this
complex.
PS1 FAD mutants alter evoked
NMDAR EPSCs and increase
neuronal vulnerability to ischaemia
in vivo
Since PS1 FAD mutants change the GLUN1 interactions
with EPHB2 and PS1, we asked whether these mutations
affect NMDAR-mediated synaptic responses. We pre-
pared acute hippocampal slices from PS1 FAD (M146V)
or WT control mice and used whole-cell patch-clamp
recordings from CA1 pyramidal cells to measure pharma-
cologically isolated NMDAR-mediated EPSCs at Schaffer
collateral-CA1 synapses. NMDAR–EPSCs were elicited by
applying stimuli of increasing intensity to presynaptic
Schaffer collaterals in the presence of bath-applied AMPA
receptor antagonist NBQX (10 lM), and GABAA receptor
antagonist Gabazine (GBZ; 10 lM), at a holding poten-
tial of þ40 mV. Activation of Schaffer collaterals evoked
NMDAR EPSCs in CA1 pyramidal neurons in both WT
and FAD mutant brain slices (Fig. 8A). However, PS1
FAD mutant M146V significantly reduced the magnitude
of the evoked NMDAR-mediated EPSCs in mutant CA1
neurons compared to WT CA1 neurons, as shown by
sample current traces (Fig. 8A) and the input–output
plots (Fig. 8B). Together, these results show that PS1
FAD mutants alter the NMDAR-mediated synaptic cur-
rents probably by affecting the PS1 association with the
NMDAR.
We next asked whether PS1 FAD mutants increase
neuronal vulnerability to ischaemia in vivo by subjecting
both wild-type and PS1 FAD mutant-expressing mice
(M146V and I213T) to middle cerebral artery occlusion
(MCAO) followed by reperfusion. No differences in
physiological parameters were observed at various stages
of the MCAO between WT and PS1 FAD mutants.
Animals were sacrificed 30 days after the onset of reper-
fusion, and number of NeuN-positive neurons was manu-
ally counted (see Materials and methods section). The
number of viable neurons was significantly reduced in
PS1 mutant mice compared to WT mice (Fig. 8C), sug-
gesting increased neuronal vulnerability to ischaemia of
brains expressing PS1 FAD mutants.
Discussion
PS1 promotes neuroprotection by
mediating factor-stimulated
association of FR with GLUN1
The underlying causes of neuronal dysfunction and death
in neurodegenerative disorders, including Alzheimer dis-
ease, are imperfectly understood thus contributing to the
lack of effective therapeutic methods (Neve and Robakis,
1998). Neurotrophic factors are known to bind cognate
receptors and protect neurons from toxic insults
(Sampaio et al., 2017) and recently we reported that the
ability of neuroprotective factors such as EFNB1 (eB1)
and BDNF to protect cortical neurons from glutamate
excitotoxicity depends on PS1 (Barthet et al., 2013), a
protein with crucial roles in neurodegeneration as PS1
mutants cause most cases of early onset autosomal dom-
inant FAD (Sherrington et al., 1995, http://www.alzfo
rum.org/mutations). Despite its central roles in synaptic
transmission, plasticity, learning and memory, over-activa-
tion of NMDAR is associated with excitotoxicity and
neuronal cell death (Arundine and Tymianski, 2003;
Hardingham, 2009; Parsons and Raymond, 2014) sug-
gesting a potential NMDAR involvement in neurodege-
nerative disorders including Alzheimer disease (Choi,
1988, 1994). It is known that treatment of cell cultures
with exogenous BDNF or eB1 stimulate formation of dy-
namic complexes of their cognate receptors, TRKB and
EPHB2 respectively, with the NMDAR receptor, a
Figure 7 Continued
ex-GLUN1 (50 nM; 4th bar). Peptide exEPHB2, however, does not abolish BDNF neuroprotection (5th bar). Data are mean 6 SEM. **P< 0.01;
one-way ANOVA with Tukey’s post hoc test, n¼ 3–5. Cell survival in the presence of glutamate is set at 100%. (upper panel). ExGLUN1 reduces
the BDNF-stimulated association of TRKB with GLUN1. Neuronal cultures were pretreated for 1 h with either exGLUN1 or BSA (50 nM)
followed by BDNF stimulation for 30 min. Neurons were lysed afterwards, and extracts were IPed with anti-TRKB followed by WB with anti-
GLUN1 or anti-TRKB antibodies. (D) Cortical neuronal cultures from WT, heterozygous (KI/WT) and homozygous (KI/KI) for PS1 FAD
(M146V) KI mouse embryonic brains were treated with BDNF for 30 min, lysed and IPed with anti-TRKB antibody, then immunoblotted with
anti-GLUN1 and anti-TRKB antibodies, respectively. The input of the IP experiment is also shown in the lower panel. (E) Cortical neuronal
cultures from WT, heterozygous (KI/WT) and homozygous (KI/KI) for PS1 FAD (I213T) KI mouse embryonic brains were treated with BDNF
for 30 min, lysed and IPed with anti-PS1 NTF (PS1) antibody, then immunoblotted with anti-GluN1. PS1 was detected under the same condition
with unboiled samples.
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process involving the binding of the extracellular domains
of EPHB2 or TRKB to the GLUN1 subunit of the
NMDAR (Suen et al., 1997; Dalva et al., 2000; Husi
et al., 2000; Henderson et al., 2001; Wang et al., 2011;
Stucky et al., 2016). However, the importance of the fac-
tor-stimulated NMDAR–FR complexes in neuroprotection
and potential roles of PS1 in their formation are unclear.
Here, we tested the role of the eB1-stimulated EPHB2–
NMDAR association in neuroprotection by using peptides
containing extracellular sequence of EPHB2 to block the
eB1-stimulated association of EPHB2 with NMDAR. Our
data show that preventing the de novo formation of the
eB1-stimulated EPHB2–GLUN1 complex abolishes the
eB1-dependent neuroprotection, showing this complex
plays central roles in the eB1-dependent neuronal survival
against toxic insults. We also found that the eB1-stimu-
lated association of EPHB2 with GLUN1 depends on PS1
and that eB1 also increases the association of PS1 with
the NMDAR, a finding consistent with reports that PS1
physically interacts with the NMDAR (Saura et al.,
2004). Similarly, we found that PS1 is needed for the
BDNF-stimulated complex of TRKB with GLUN1 and
that artificial peptides that prevent formation of this com-
plex also abolish the BDNF-dependent neuroprotection
indicating that the association of TRKB with the
NMDAR regulates neuroprotective activities of BDNF.
Together with previous reports that PS1 is required for
the eB1- and BDNF-dependent neuroprotection against
excitotoxicity (Barthet et al., 2013), our data support a
mechanism by which PS1 promotes neuroprotection by
mediating factor-stimulated associations of NMDAR with
FR, an association critical to neuroprotection against
neurotoxicity. It has also been suggested that the synaptic
localization of NMDARs is regulated through physical
associations with PS1 (Saura et al., 2004). Combined
with evidence that activation of synaptic NMDAR is pro-
survival (Hardingham and Bading, 2010; Parsons and
Raymond, 2014) our data suggests that PS1-regulated
neuroprotective mechanism may also dependent, at least
in part, on the activation of NMDARs being complexed
with PS1 in the synaptic compartment.
It is known that PS1 interacts with EPHB2 (Litterst
et al., 2007) and we show here that eB1, a ligand of
EPHB2, stimulates the association of EPHB2 and PS1
with the GLUN1 subunit of the NMDAR (Figs 1A and
5A) but has no effect on the PS1–EPHB2 association
(Supplementary Fig. 7). Combined with our findings that
PS1 is necessary for the eB1-stimulated association of
Figure 8 PS1 FAD mutant decreases NMDAR EPSCs in the CA1 region of mouse hippocampal slices and increases neuronal
vulnerability after ischaemia in vivo. (A) Representative EPSC traces from WT (black) and heterozygous for PS1 FAD mutant M146V
(M146V/WT) (red) CA1 neurons. Traces are averages of 5 NMDAR EPSCs recorded in the presence of 10 mM NBQX and 10 mM GBZ.
(B) Input–output plot showing significantly reduced amplitudes of NMDAR EPSCs in PS1 FAD mutant-expressing neurons in comparison with
WT neurons at higher stimulation intensities. The values in parentheses indicate the number of neurons/mice used in the analysis. Data are
expressed as mean þ SEM; P¼ 0.013, F¼ 6.36, two-way ANOVA. (C) WT (WT/WT), M146V (WT/M146V) and I213T (WT/I213T)
heterozygous mice were subjected to MCAO. Brains were isolated and sectioned 30 days later, followed by counting viable neurons with stereo
investigator software. Number of live neurons in the MCAO lesioned cortical area was normalized to number of neurons in the contralateral
side of each section. *P < 0.05, two-tailed unpaired t-test versus WT, n¼ 3 (WT), n¼ 6 (WT/M146V), n¼ 6 (WT/I213T).
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EPHB2 with GLUN1, our data support a model where
binding of eB1 to constitutive EPHB2–PS1 complexes
stimulates recruitment of both proteins to GLUN1, a pro-
cess that leads to de novo formation of the neuroprotec-
tive PS1–EPHB2–NMDAR association (see graphical
abstract). Our data also show that the role of PS1 in the
eB1-stimulated association of EPHB2 with GLUN1 is in-
dependent of c-secretase activity. Similarly, c-secretase
inhibitors had no effect on the BDNF-stimulated associ-
ation of TRKB with GLUN1. These findings are in agree-
ment with reports that the neuroprotective activities of
eB1 and BDNF are independent of c-secretase (Barthet
et al., 2013).
PS1 FAD mutants decrease factors-
stimulated associations of GLUN1
with FRs and block neuroprotection
PS1 mutants cause FAD, a condition that shares clinical
and neuropathological phenotypes with the more com-
mon sporadic Alzheimer disease (SAD) suggesting that
both Alzheimer disease forms share overlapping mecha-
nisms (Lippa et al., 1996). We thus explored potential
effects of PS1 FAD mutants on the neuroprotective activ-
ities of EFNB1 (eB1) and BDNF. To minimize potential
interference or toxic effects found in protein overexpres-
sion mouse models (Saito et al., 2016), we used neuronal
cultures and brain tissue from KI mouse models where
exogenous PS1 FAD mutants show similar expression lev-
els as endogenous genes (see Results section). We discov-
ered that in contrast to WT neurons, neurons expressing
PS1 FAD mutant M146V or I213T in either heterozygous
or homozygous state are rescued from excitotoxicity by
neither eB1 nor BDNF. These data show that PS1 FAD
mutants have dominant negative effects on the neuropro-
tective activities of BDNF and eB1 and suggest that FAD
mutants interfere with factors-dependent neuroprotective
mechanisms. Importantly, FGF-dependent neuroprotection
is not affected by PS1 FAD mutants (Supplementary Fig.
4), indicating that these mutants selectively interfere with
the activity of a limited number of neuroprotective fac-
tors. In agreement with our data that the factor-stimu-
lated association of FR with GLUN1 is crucial to
neuroprotection, we found that the ability of eB1 to
stimulate the association of EPHB2 with GLUN1 deceases
dramatically in neurons expressing PS1 FAD mutants.
These data support the theory that PS1 FAD mutants re-
duce the eB1-dependent neuroprotection by decreasing
the eB1-stimulated association of its receptor EPHB2 with
GLUN1 (see graphical abstract). Similarly, FAD mutants
inhibit the BDNF-dependent neuroprotection and the
BDNF-stimulated association of TRKB with GLUN1 indi-
cating that these mutants block the neuroprotective activ-
ity of BDNF by inhibiting the BDNF-dependent
association of TRKB with GLUN1.
Using co-IP and immunostaining experiments we made
the unexpected observation that compared to WT con-
trols, cortical neuronal cultures and mouse brain tissue
expressing PS1 FAD mutants have increased amounts of
constitutive GLUN1 complexes with EPHB2 and PS1 and
show increased co-localization of GLUN1 with EPHB2
and PS1 (see Results section). Importantly, in contrast to
WT complexes which are stimulated in response to eB1
treatment, the PS1–GLUN1 and EPHB2–GLUN1 com-
plexes of FAD mutant-expressing neurons form independ-
ent of eB1 and do not change in response to eB1
treatment. Furthermore, although the inducible WT
PS1–GLUN1 complex dissociates rapidly following eB1
withdrawal, the PS1–GLUN1 complex of FAD mutant-
expressing neurons show little or no dissociation follow-
ing withdrawal of eB1 (Fig. 6C and D) supporting the
conclusion that PS1 FAD mutants over-stabilize the PS1–
GLUN1 complex independent of eB1. It is tempting to
speculate that over-stabilization of the PS1–GLUN1 com-
plex changes the dynamic nature of the interactions of its
protein components affecting its neuroprotective func-
tions. Together, our data show that the PS1–GLUN1
complex of WT neurons differs from that formed in neu-
rons expressing FAD mutants. We explored further the
physiological relevance of our findings by asking whether
human brains expressing PS1 FAD mutants have
increased levels of the GLUN1–PS1 complex. We found
that post-mortem brain tissue from two siblings carrying
the PS1 FAD mutant S170F had increased levels of the
GLUN1–PS1 complex. Additional brain samples however,
carrying distinct PS1 FAD mutants showed no increased
levels of this complex. Our inability to detect increased
PS1–GLUN1 complex in brain tissue from these FAD
mutant carriers may be related to the quality of the post-
mortem brain tissue or an indication that the increase of
the PS1–GLUN1 complex is mutant-specific.
It has been proposed that glutamate excitotoxicity and
deficiency in neurotrophic support by BDNF play import-
ant roles in neurodegenerative disorders such as
Alzheimer disease (Almeida et al., 2005; Zuccato and
Cattaneo, 2009) and that BDNF promotes neuroprotec-
tion by decreasing the toxic signalling of NMDAR (Lau
et al., 2015). Our findings that eB1 and BDNF increase
neuroprotection by stimulating interactions of their re-
spective receptors with NMDAR suggest that these inter-
actions decrease NMDAR-mediated excitotoxicity.
Furthermore, that PS1 FAD mutants impair the factor-
stimulated neuroprotective interactions of FR with
GLUN1 suggests that restoring these interactions might
be beneficial to Alzheimer disease patients.
PS1 FAD mutants affect NMDAR
EPSCs and increase neuronal
vulnerability to ischaemia
In hippocampus, NMDARs are required for the induction
of long-term potentiation and formation of long-term
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memory (Bliss and Collingridge, 1993; Tsien et al.,
1996). Using acute hippocampal slices from PS1 M146V
mutant mice, we found that the magnitude of evoked
NMDAR-mediated synaptic currents in CA1 across a
range of Schaffer-collateral stimulation strengths, is sig-
nificantly reduced compared to WT, suggesting impaired
NMDAR synaptic neurotransmission in brain of mice
expressing FAD mutants. Such a deficit in synaptic
NMDAR signal strength may underlie the reported spa-
tial memory deficits displayed by these PS1 FAD mutant
mice (Sun et al., 2005). Our finding that the FAD
mutants also change the constitutive association of PS1
with NMDAR supports the suggestion that this associ-
ation plays important roles in the NMDAR synaptic
transmission. Furthermore, in agreement with our in vitro
results of Fig. 2A, the in vivo data of Fig. 8C show that
brain neurons of mice expressing PS1 FAD mutants also
show increased vulnerability to ischaemic lesions suggest-
ing that such mutants render neurons vulnerable to exci-
totoxicity in vivo, presumably by reducing the activity of
factors-dependent brain neuroprotective mechanisms. In
addition, that these mutants also change the association
of PS1 with NMDAR and reduce its synaptic currents
which is believed to be neuroprotective (Ikonomidou
et al., 1999; Hetman and Kharebava, 2006; Hardingham
and Bading, 2010; Parsons and Raymond, 2014), sup-
ports the theory that the PS1–NMDAR interactions may
affect additional neuronal survival mechanisms by modu-
lating the synaptic activity of the NMDAR.
In summary, our study reveals novel PS1-dependent
neuroprotective mechanisms of neurotrophic factors
BDNF and EFNB1. These mechanisms are perturbed by
PS1 FAD mutants leading to decreased neuroprotection
against neurotoxicity. Our data suggest a mechanism by
which PS1 FAD mutants may increase neurodegeneration
by inactivating factor-dependent neuroprotection render-
ing neurons vulnerable to commonly occurring brain tox-
icities such as excitotoxicity, oxidative stress, ischaemia
and traumatic brain injuries (Choi, 1988; Mattson,
2003). It is tempting to speculate that over many years,
reduced neuroprotection to toxic episodes will cause sig-
nificant neurodegeneration that can lead to dementia. It
is also known that mature KI transgenic mice expressing
the PS1 FAD variants used in this study show little or no
neuropathological hallmarks of Alzheimer disease (Guo
et al., 1999; Nakano et al., 1999). Thus, PS1 FAD
mutants can increase neuronal vulnerability to toxic
insults and cause electrophysiological abnormalities in the
absence of Alzheimer disease neuropathology, supporting
the suggestion that in Alzheimer disease, neuronal abnor-
malities may be upstream of the neuropathological hall-
marks (Robakis, 2011). Combined with evidence that
neuronal damage by excitotoxicity and oxidative stress
leads to neuropathology similar to that of Alzheimer dis-
ease (Misonou et al., 2000; Lesne et al., 2005; Melov
et al., 2007; Liang et al., 2009; Bordji et al., 2010),
chronic reduction of neuroprotection against
neurotoxicity may lead to dementia of the Alzheimer dis-
ease type. The underlying mechanisms by which FAD
mutants affect the survival complexes leading to
decreased neuroprotection, may offer novel targets for
therapeutic intervention.
Supplementary material
Supplementary material is available at Brain
Communications online.
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